Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China

References

• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–S55. doi:10.1002/hep.v49.5s.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med. 2017;11:490–501. doi:10.1007/s11684-017-0598-4.
   PubMed Web of Science ®Google Scholar
• Cui FQ, Zhuang H. Hepatitis B control in China:progress,challenges and strategies. Chin J Viral Dis. 2016;02:81–87.
   Google Scholar
• Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16:e82–8. doi:10.1016/j.ijid.2011.10.009.
   PubMed Web of Science ®Google Scholar
• Xu AQ, Zhang L. Immunization strategy of hepatitis B vaccine among adults in China: evidence based-medicine and consideration(in Chinese). Zhonghua Yu Fang Yi Xue Za Zhi. 2016;50:473–77. doi:10.3760/cma.j.issn.0253-9624.2016.06.001.
   PubMedGoogle Scholar
• Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332:328–36. doi:10.1136/bmj.38719.435833.7C.
   PubMed Web of Science ®Google Scholar
• He H, Zhou Y, Xie S. Assessment of the duplicate notifiable reporting of hepatitis B infection in Zhejiang province, China, 2005–2015. Vaccine. 2017;35:4702–06. doi:10.1016/j.vaccine.2017.07.039.
   PubMed Web of Science ®Google Scholar
• Zhou Y, He H, Deng X, Yan R, Tang X, Xie S, Yao J. Significant reduction in notification and seroprevalence rates of hepatitis B virus infection among the population of Zhejiang Province, China, aged between 1 and 29years from 2006 to 2014. Vaccine. 2017;35:4355–61. doi:10.1016/j.vaccine.2017.06.078.
   PubMed Web of Science ®Google Scholar
• Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine. 2013;31:1864–69. doi:10.1016/j.vaccine.2013.01.020.
   PubMed Web of Science ®Google Scholar
• Yin J, Ji Z, Liang P, Wu Q, Cui F, Wang F, Liang X, Zhuang G. The doses of 10 mug should replace the doses of 5 mug in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine. 2015;33:3731–38. doi:10.1016/j.vaccine.2015.05.082.
   PubMedGoogle Scholar
• Chen Y-S, Zheng H, Liu Y-M, Wang F-Z, Wu Z-H, Miao N, Sun X-J, Zhang G-M, Cui F-Q, Liang X-F, et al. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. Hum Vaccin Immunother. 2016;12:1838–46. doi:10.1080/21645515.2016.1141845.
   PubMed Web of Science ®Google Scholar
• Zhou M, Li Y, Wang H, Zeng X, Wang L, Liu S, Liu YN, Liang XF. Analysis on life expectancy and healthy life expectancy in China, 1990–2015. Chin J Epidemiol. 2016;37:1439–43. doi:10.3760/cma.j.issn.0254-6450.2016.11.001.
   Google Scholar
• Zhou Y, He H, Deng X, Yan R, Tang X, Xie S. Comparative analysis on actual cost and reasonable cost of expanded program on immunization in Zhejiang. Chin Health Econ. 2018;37:86–89.
   Google Scholar
• Xin CG. Observation of immune effect of hepatitis B vaccine on newborn babies in linyi city. Occup Health. 2011;27:2540–42.
   Google Scholar
• Xiong JX, Tang YZ, XIONG XL. Immune effect of two different hepatitis b vaccines. J Med Pest Control. 2013;29:219.
   Google Scholar
• Zhang YH, Kuang G, Li QQ. Study on immune effect of hepatitis b vaccine. Contemp Med. 2014;28:51.
   Google Scholar
• Yang SJ, Dong HJ. Meta analysis and systematic review of the effect of hepatitis B immunoglobulin combined with hepatitis B vaccines. Chin J Vaccines Immunization. 2013;19:319–24.
   Google Scholar
• Zhu GQ. Effect of recombinant hepatitis b vaccine combined with hepatitis b immunoglobulin to block mother-to-child transmission of hepatitis b and related factors. Maternal and Child Health Care China. 2017;32:965–68.
   Google Scholar
• Yu LP, Chen FF, Wang L, CHEN GJ. Stusy on the effect of combined immunization and passive intervention on mother-to-child transmission of HBV. Chin J Rural Med Pharm. 2014;21:33–34.
   Google Scholar
• Yao J, Chen YD, Lou B, REN JJ. Evaluation of hepatitis B vaccination with different dose on block ingmother-to-child transmission. Dis Surveillance. 2010;25:981–83.
   Google Scholar
• Zhang L, Gui XE, Teter C, Zhong H, Pang Z, Ding L, Li F, Zhou Y, Zhang L. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. Vaccine. 2014;32:6091–97. doi:10.1016/j.vaccine.2014.08.078.
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang G, Zheng H, Miao N, Shen L, Wang F, Dong P, Du F, Chen C, Zhang X, et al. Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China. Vaccine. 2017;35:4229–35. doi:10.1016/j.vaccine.2017.06.019.
   PubMed Web of Science ®Google Scholar
• Zhou SY, Bian GL, Ma R, Ni HX, Fang T, Chen XY. A study on immunologic response at different periods with different hepatitis B vaccine in infants. Zhejiang Prev Med. 2015;27:466–68.
   Google Scholar
• Liu SK, Huang ML, Ge BX, Wang F, HU LL, Hu DB. Observation on immunogenicity of different formulation of hepatitis B vaccine in newborns. Mod Preventive Med. 2014;41:2001–03.
   Google Scholar
• Zhu FC, Sun KX, Pan HX, Yang ZH, Lu Y, Liang ZL, Liang X-F, Wang F-Z, Zeng Y, Li J, et al. The immunogenicity in healthy infants and efficiency to prevent mother to child transmission of Hepatitis B virus of a 10mug recombinant yeast-derived Hepatitis B vaccine (Hep-KSC). Vaccine. 2016;34:2656–62. doi:10.1016/j.vaccine.2016.04.042.
   PubMed Web of Science ®Google Scholar
• Su WJ, Chen SF, Yang CH, Chuang PH, Chang HF, Chang MH. The impact of universal infant hepatitis B immunization on reducing the hepatitis B carrier rate in pregnant women. J Infect Dis. 2019;220(7):1118–26.
   Web of Science ®Google Scholar
• Yan WW, Zhang Y, Lei YF, Wang SL, Li RF. An evaluation of immune persistence of neonates vaccinated with yeast hepatitis b vaccine. Sichuan Med J. 2005;26:1149–50.
   Google Scholar
• Huang ZY, Zhu JQ, Chen Q, Huang XM, Pi SC, Li DQ. Surveillance on immunization effects of hepatitis B vaccine in 981 infants. Pract Preventive Med. 2008;15:1438–39.
   Google Scholar
• Wei KP, Zhu FC, Liu JX, Yan L, Lu Y, Zhai XJ, Chang Z-J, Zeng Y, Li J, Zhuang H, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study. Vaccine. 2018;36:256–63. doi:10.1016/j.vaccine.2017.11.037.
   PubMed Web of Science ®Google Scholar
• Lin X, Guo Y, Zhou A, Zhang Y, Cao J, Yang M, Xiao F, Zhang B, Du Y. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: a hospital-based study and a meta-analysis. Pediatr Infect Dis J. 2014;33:897–903. doi:10.1097/INF.0000000000000315.
   PubMed Web of Science ®Google Scholar
• Kang W, Ding Z, Shen L, Zhao Z, Huang G, Zhang J, Xiong Q, Zhang S, Zhang S, Wang F, et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China. Vaccine. 2014;32:3362–66. doi:10.1016/j.vaccine.2014.04.045.
   PubMed Web of Science ®Google Scholar
• Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94–98. doi:10.1093/oxfordjournals.aje.a112370.
   PubMed Web of Science ®Google Scholar
• Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–74. doi:10.1056/NEJM197504102921503.
   PubMed Web of Science ®Google Scholar
• zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y, Tan H, Liu J, Zhang Y, Zhang L, et al. Annual economic burden of hepatitis B virus‐related diseases among hospitalized patients in twelve cities in China. J Viral Hepat. 2016;23:202–10. doi:10.1111/jvh.2016.23.issue-3.
   PubMed Web of Science ®Google Scholar
• Jin H, Wang B, Gao Q, Chao J, Wang S, Tian L, Liu P. Comparison between EQ-5D and SF-6D utility in Rural residents of Jiangsu Province, China. PLoS One. 2012;7:e41550. doi:10.1371/journal.pone.0041550.
   PubMed Web of Science ®Google Scholar
• Xiao M, Wang H, Zhang W, Pang XH. Cost-effectiveness analysis of hepatitis B vaccination strategy for high risk adults in Beijing. Chin J Dis Control Prev. 2015;19:730–34.
   Google Scholar
• Jia YX, Cui FQ, Li L, Zhang DL, Zhang GM, Wang FZ, Gong XH, Zheng H, Wu ZH, Miao N, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23:2355–63. doi:10.1007/s11136-014-0670-3.
   PubMed Web of Science ®Google Scholar
• Zhou MG, Li YC, Wang HD, Zeng XY, Wang LJ, Liu SW, Liu YN, Liang XF. Analysis on life expectancy and healthy life expectancy in China, 1990–2015. Chin J Epidemiol. 2016;37:1439–43. doi:10.3760/cma.j.issn.0254-6450.2016.11.001.
   Google Scholar
• Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28:2356–59. doi:10.1016/j.vaccine.2009.06.035.
   PubMed Web of Science ®Google Scholar
• Ji. ZH. The cost-effectivness analysis of hepatitis B immunization strategy in Chinese newborns. Xi’an Xi’an Jiaotong University; 2012.
   Google Scholar
• Zhang Y, Zhang H, Elizabeth A, Liu XQ. Epidemiology of hepatitis B and associated liver diseases in china. Chin Med Sci Jl. 2012;27:243–48. doi:10.1016/S1001-9294(13)60009-7.
   Google Scholar
• Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, et al. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. Hum Vaccin Immunother. 2014;10:2983–91. doi:10.4161/hv.29944.
   PubMed Web of Science ®Google Scholar
• Huifang H, Chen H. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine. 2009;27:6770–76. doi:10.1016/j.vaccine.2009.08.082.
   PubMed Web of Science ®Google Scholar
• Yang PC. Development of markov models for hepatitis B vaccination or treatment and cost-effectiveness analysis of prophylactic entecavir use for population based-on community in China Guangdong pharmaceutical university. 2016.
   Google Scholar
• Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310:974–76. doi:10.1001/jama.2013.276701.
   PubMed Web of Science ®Google Scholar
• Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62:S76–86. doi:10.1016/j.jhep.2015.01.018.
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993;253:197–201.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Park HJ, Chu MA, Choi BS, Choe BH. The rate of conversion from immune-tolerant phase to early immune-clearance phase in children with chronic hepatitis B virus infection. Pediatr Gastroenterol Hepatol Nutr. 2014;17:41–46. doi:10.5223/pghn.2014.17.1.41.
   PubMedGoogle Scholar
• Wong WW, Woo G, Heathcote EJ, Krahn M. Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol. 2013;27:137–47. doi:10.1155/2013/924640.
   PubMed Web of Science ®Google Scholar
• Lim TH, Gane E, Moyes C, Borman B, Cunningham C. Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Maori: results from a 28-year follow-up study. Gut. 2014;64:966–72. doi:10.1136/gutjnl-2013-306247.
   PubMed Web of Science ®Google Scholar
• Geier A, Gartung C, Dietrich CG. Hepatitis B e antigen and the risk of hepatocellular Carcinoma. N Engl J Med. 2002;347:1721.
   PubMed Web of Science ®Google Scholar
• Chen JG, Lu JH, Zhu YR, Zhu J, Zhang YH. A thirty-one year prospective follow-up program on the HBsAg carrier state and primary liver cancer in Qidong, China. Chin J Epidemiol. 2010;31:721–26.
   Google Scholar
• Yan HJ. Long-term efficacy of hepatitis b vaccine and HBeAg seroconversion during chroric infection. Shanghai: Fudan University; 2013.
   Google Scholar
• Chen CR. The predictive factors of spontaneous surface antigen loss in chronic hepatitis B virus carriers. Xiamen: Xiamen University; 2013.
   Google Scholar
• Barbosa C, Smith EA, Hoerger TJ, Fenlon N, Schillie SF, Bradley C, Murphy TV. Cost-effectiveness analysis of the national perinatal hepatitis B prevention program. Pediatrics. 2014;133:243–53. doi:10.1542/peds.2013-0718.
   PubMed Web of Science ®Google Scholar
• Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun C, Liaw Y, Chen C, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2014,19(1):71–73. doi:10.1053/j.gastro.2010.01.042.
   Web of Science ®Google Scholar
• Ren TT, Xu GH, Li CX. A natural history of HBsAg inactive carrier. Chin Hepatol. 2014;71–73.
   Google Scholar
• Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You S, Iloeje UH, Chen C. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–82. doi:10.1053/j.gastro.2010.04.048.
   PubMed Web of Science ®Google Scholar
• Liu J, Lee MH, Batrlautermann R, Jen CL, Iloeje UH, Lu SN, Wang L-Y, You S-L, Hsiao CK, Yang H-I, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58:853–60. doi:10.1016/j.jhep.2012.12.006.
   PubMed Web of Science ®Google Scholar
• Kwak MS, Cho EJ, Jang ES, Lee JH, Yu SJ, Kim YJ, Yoon J-H, Lee H-S. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Digestion. 2011;84:23–28. doi:10.1159/000333211.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, et al. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol. 2014;49:538–46. doi:10.1007/s00535-013-0821-2.
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Chen CL, Yang HC, Su TH, Wang CC, Yang W-T, Kuo SFT, Liu C-H, Chen P-J, et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis. 2013;208:584–93. doi:10.1093/infdis/jit209.
   PubMed Web of Science ®Google Scholar
• Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses. PLoS One. 2014;9:e107177. doi:10.1371/journal.pone.0107177.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Luo M, Chen J, He H, Deng X, Xie S, Fang Y. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China. Vaccine. 2019;37:3071–77. doi:10.1016/j.vaccine.2019.04.057.
   PubMed Web of Science ®Google Scholar
• Lee D, Shin HY, Park SM. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea. Cost Eff Resour Allocation. 2018;16:2–11. doi:10.1186/s12962-018-0088-9.
   PubMed Web of Science ®Google Scholar
• Stevens CE, Toy P, Kamili S, Taylor PE, Tong MJ, Xia GL, Vyas GN. Eradicating hepatitis B virus: the critical role of preventing perinatal transmission. Biologicals. 2017;50:3–19. doi:10.1016/j.biologicals.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Wen WH, Lai MW, Chang MH. A review of strategies to prevent mother-to-infant transmission of hepatitis B virus infection. Expert Rev Gastroenterol Hepatol. 2016;10:317–30. doi:10.1586/17474124.2016.1120667.
   PubMed Web of Science ®Google Scholar
• Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics. 2013;131:e1135–43. doi:10.1542/peds.2012-1262.
   PubMed Web of Science ®Google Scholar
• Fan L, Owusu-Edusei K Jr., Schillie SF, Murphy TV. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology. 2016;63:1471–80. doi:10.1002/hep.v63.5.
   PubMed Web of Science ®Google Scholar
• Devine A, Harvey R, Min AM, Gilder MET, Paw MK, Kang J, Watts I, Hanboonkunupakarn B, Nosten F, McGready R, et al. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Infect Dis. 2017;17:552. doi:10.1186/s12879-017-2660-x.
   PubMed Web of Science ®Google Scholar
• Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Global Health. 2016;4:E568–E78. doi:10.1016/S2214-109X(16)30101-2.
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215. doi:10.2165/00019053-200826030-00004.
   PubMed Web of Science ®Google Scholar